Advertisement

Interaction Between the Haptoglobin Genotype and Vitamin E on Cardiovascular Disease in Diabetes

  • Irit HochbergEmail author
  • Elliot M. Berinstein
  • Uzi Milman
  • Chen Shapira
  • Andrew P. Levy
Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Lifestyle Management to Reduce Diabetes/Cardiovascular Risk

Abstract

Purpose of Review

Despite compelling evidence regarding the importance of oxidant stress in the development of vascular complications and observational studies suggesting that vitamin E may be protective from these complications, multiple clinical trials have failed to show benefit from vitamin E supplementation in the prevention of vascular complications in diabetes. One possible explanation for this failure of vitamin E may have been inappropriate patient selection. This review seeks to provide the clinical evidence and mechanistic basis for why a subset of individuals defined by their haptoglobin (Hp) genotype may derive cardiovascular protection by vitamin E supplementation.

Recent Findings

Clinical trial data from the HOPE, ICARE, and WHS studies is presented showing a pharmacogenomic interaction between the Hp genotype and vitamin E on the development of CVD. Specifically, in individuals with diabetes and the Hp2-2 genotype, vitamin E has been shown to be associated with an approximately 35% reduction in CVD. Cardioprotection by vitamin E in individuals with the Hp2-2 genotype appears to be mediated in part by an improvement in HDL functionality as demonstrated in three independent trials in both type 1 diabetes and type 2 diabetes.

Summary

Vitamin E may provide benefit in reducing CVD in Hp2-2 individuals with diabetes. However, in order for this pharmacogenomic algorithm to be accepted as a standard of care and used clinically, an additional large prospective study will need to be performed.

Keywords

Vitamin E Haptoglobin Cardiovascular disease High-density lipoproteins Oxidative stress 

Notes

Compliance with Ethical Standards

Conflict of Interest

Irit Hochberg, Elliot M. Berinstein, Uzi Milman, and Chen Shapira declare that they have no conflict of interest.

Andrew P. Levy reports that his institution is the owner of a patent which claims to use haptoglobin genotyping to predict the risk of developing cardiovascular disease in diabetes and the use of vitamin E to reduce this risk; and it is licensed to In Vitro (patent is owned by BioRap Technologies of the Technion Israel Institute of Technology).

Human and Animal Rights and Informed Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in any of the studies reviewed in this article. This article does not contain any studies with animals performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320(14):915–24. doi: 10.1056/NEJM198904063201407.CrossRefPubMedGoogle Scholar
  2. 2.
    Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL—an evolving field. Nat Clin Pract Endocrinol Metab. 2006;2(9):504–11. doi: 10.1038/ncpendmet0245.CrossRefPubMedGoogle Scholar
  3. 3.
    Wolf G. The discovery of the antioxidant function of vitamin E: the contribution of Henry A. Mattill J Nutr. 2005;135(3):363–6.PubMedGoogle Scholar
  4. 4.
    Mason KE. The first two decades of vitamin E. Fed Proc. 1977;36(6):1906–10.PubMedGoogle Scholar
  5. 5.
    Burton GW, Cheng SC, Webb A, Ingold KU. Vitamin E in young and old human red blood cells. Biochim Biophys Acta. 1986;860(1):84–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Fahrenholtz SR, Doleiden FH, Trozzolo AM, Lamola AA. On the quenching of singlet oxygen by alpha-tocopherol. Photochem Photobiol. 1974;20(6):505–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Kagan VE, Serbinova EA, Forte T, Scita G, Packer L. Recycling of vitamin E in human low density lipoproteins. J Lipid Res. 1992;33(3):385–97.PubMedGoogle Scholar
  8. 8.
    Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328(20):1450–6. doi: 10.1056/NEJM199305203282004.CrossRefPubMedGoogle Scholar
  9. 9.
    Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328(20):1444–9. doi: 10.1056/NEJM199305203282003.CrossRefPubMedGoogle Scholar
  10. 10.
    Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol. 2000;20(7):1716–23.CrossRefPubMedGoogle Scholar
  11. 11.
    • Vardi M, Levy NS, Levy AP. Vitamin E in the prevention of cardiovascular disease: the importance of proper patient selection. J Lipid Res. 2013;54(9):2307–14. doi: 10.1194/jlr.R026641. This study provides a metanalysis of all studies examining the association between the Hp type and CVD and the pharmacogenomic data concerning vitamin E and CVD in individuals segregated by Hp types CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Virtamo J, Rapola JM, Ripatti S, Heinonen OP, Taylor PR, Albanes D, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158(6):668–75.CrossRefPubMedGoogle Scholar
  13. 13.
    de Gaetano G, Primary PP. Low-dose aspirin and vitamin E in people at cardiovascular risk (vol 357, pg 89, 2001). Lancet. 2001;357(9262):1134.CrossRefGoogle Scholar
  14. 14.
    Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300(18):2123–33. doi: 10.1001/jama.2008.600.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356(9237):1213–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol. 2002;40(11):1984–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care. 2003;26(9):2628–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes. 2005;54(9):2802–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92(11):1193–200. doi: 10.1161/01.RES.0000076889.23082.F1.CrossRefPubMedGoogle Scholar
  22. 22.
    Raynes JG, Eagling S, McAdam KP. Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol. 1991;83(3):488–91.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Murray RK, Connell GE, Pert JH. The role of haptoglobin in the clearance and distribution of extracorpuscular hemoglobin. Blood. 1961;17:45–53.PubMedGoogle Scholar
  24. 24.
    Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409(6817):198–201. doi: 10.1038/35051594.CrossRefPubMedGoogle Scholar
  25. 25.
    Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42(10):1589–600.PubMedGoogle Scholar
  26. 26.
    Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet. 1982;12:189–261. 453-4CrossRefPubMedGoogle Scholar
  27. 27.
    Robson EB, Polani PE, Dart SJ, Jacobs PA, Renwick JH. Probable assignment of the alpha locus of haptoglobin to chromome 16 in man. Nature. 1969;223(5211):1163–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Awadallah S, Hamad M. The prevalence of type II diabetes mellitus is haptoglobin phenotype-independent. Cytobios. 2000;101(398):145–50.PubMedGoogle Scholar
  29. 29.
    Wejman JC, Hovsepian D, Wall JS, Hainfeld JF, Greer J. Structure and assembly of haptoglobin polymers by electron microscopy. J Mol Biol. 1984;174(2):343–68.CrossRefPubMedGoogle Scholar
  30. 30.
    Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):154–60. doi: 10.1056/NEJM200001203420302.CrossRefPubMedGoogle Scholar
  31. 31.
    Levy AP, Gerstein HC, Miller-Lotan R, Ratner R, McQueen M, Lonn E, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care. 2004;27(11):2767.CrossRefPubMedGoogle Scholar
  32. 32.
    Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):56–65. doi: 10.1001/jama.294.1.56.CrossRefPubMedGoogle Scholar
  33. 33.
    Blum S, Vardi M, Levy NS, Miller-Lotan R, Levy AP. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis. 2010;211(1):25–7. doi: 10.1016/j.atherosclerosis.2010.02.018.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol. 2008;28(2):341–7. doi: 10.1161/ATVBAHA.107.153965.CrossRefPubMedGoogle Scholar
  35. 35.
    Assmann G, Schulte H, von Eckardstein A, Huang YD. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124:S11–20. doi: 10.1016/s0021-9150(96)90501-8.CrossRefPubMedGoogle Scholar
  36. 36.
    Tall AR. An overview of reverse cholesterol transport. Eur Heart J. 1998;19(Suppl A):A31–5.PubMedGoogle Scholar
  37. 37.
    Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H, et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem. 2007;282(32):23698–707. doi: 10.1074/jbc.M702163200.CrossRefPubMedGoogle Scholar
  38. 38.
    Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes. 2008;57(10):2794–800. doi: 10.2337/db08-0450.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R, et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res. 2007;101(1):106–10. doi: 10.1161/CIRCRESAHA.107.149435.CrossRefPubMedGoogle Scholar
  40. 40.
    • Asleh R, Levy NS, Doros G, Costacou T, Robinson JG, Blum S, et al. Haptoglobin genotype as a determinant of benefit or harm from niacin for participants with diabetes. J Am Coll Cardiol. 2016;67(21):2553–4. doi: 10.1016/j.jacc.2016.03.533. This article provides an example of how HDL function varies by HDL genotype discussing that over 50% of all Hp2-2 DM individuals have dysfunctional proatherogenic HDL CrossRefPubMedGoogle Scholar
  41. 41.
    • Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–63. doi: 10.1056/NEJMra1510059. The concept and details of a low-cost clinical trial such as proposed in the review are introduced and explained CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Irit Hochberg
    • 1
    Email author
  • Elliot M. Berinstein
    • 2
  • Uzi Milman
    • 2
    • 3
  • Chen Shapira
    • 2
    • 3
  • Andrew P. Levy
    • 2
  1. 1.Institute of Endocrinology, Diabetes and MetabolismRambam HealthCare CampusHaifaIsrael
  2. 2.Technion Faculty of MedicineTechnion Israel Institute of TechnologyHaifaIsrael
  3. 3.Clalit Health ServicesHaifaIsrael

Personalised recommendations